Related Experiment Video
Updated: Apr 26, 2026

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
Biosimilar insulins are coming: what they are, what you need to know
Steven Edelman1, William H Polonsky, Christopher G Parkin
1University of California San Diego , San Diego, CA , USA.
Background:
Many branded analog insulins will lose patent protection during the next few years. In response, a number of companies are developing biosimilar insulins, which have the potential to lower healthcare costs and increase patient access. Although these products are not yet available in the US, it is important that patients, payers and clinicians be aware of the potential benefits as well as concerns associated with biosimilar insulins.
Scope:
This report provides information about these new products and discusses key questions clinicians should consider regarding biosimilar insulin.
Conclusion:
The biosimilar insulins being developed have the potential to provide clinical benefits that are similar to current insulin analogs at a more affordable price, thereby allowing more patients greater access to these effective therapies. However, industry and regulatory agencies must proceed with caution in bringing these new insulins to market. Clinicians must be aware of how availability of these new medications may impact patients' adherence to their treatment regimens and begin taking steps now to address these potential issues.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Production of Pharmaceuticals
Oral Hypoglycemic Agents: Glinides

